Skip to main content
main-content

03-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The ADAURA trial

Roy Herbst discusses the ADAURA trial investigating the postoperative use of osimertinib in patients with EGFR-mutated non-small-cell lung cancer, and comments on the potential for using it in the neoadjuvant setting (4:55).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits